Join our daily newsletter At The Bell to receive exclusive market insights
- Respiri (RSH) has included a recurring monthly revenue model to transform into an e-health software-as-a-service player
- The company is set to complete the first 500 devices of the wheezo asthma management app by January next year
- The pricing model for wheezo will encompass an ongoing monthly service subscription fee of roughly $5-10 which is likely to drive recurring revenue
- According to the Global Asthma Report from 2018, there are approximately 339 million people suffering from asthma
- Respiri’s wheezo device is set to help reduce hospitalisation rates and help patients better manage the disease
- Despite the news, the company is down 1.05 per cent with shares trading at 9.4 cents each
Respiri (RSH) has included a recurring monthly revenue model to transform into an e-health software-as-a-service (SaaS) player.
Respiri will have the first 500 batch of devices completed in January 2020 and is completing the features of the multi-dimensional wheezo asthma management application .
The pricing model for wheezo will encompass an ongoing monthly service subscription fee ($5-10), which will be applied once the product is purchased.
“The monetisation of the wheezo app will drive recurring revenue will transform Respiri into a SaaS e-health company,” CEO Marjan Mikel said.
According to the Global Asthma Report from 2018, there are approximately 339 million people in the developed world with asthma and this number is only increasing.
“Asthma is a chronic disease that requires ongoing daily treatment and now monitoring to better equip people manage their condition. This has not been possible up until now,” Marjan added.
Respiri is in the process of conducting two clinical studies to validate its technology for monitoring wheeze. The data acquisition for the first stethoscope study has been completed and analysis has started.
The second study to correlate wheeze rates against current standard asthma measure, is also in process.
These studies are being conducted under the guidance of Professor Bruce Thompson and the Medical and Scientific Advisory Committee.
The committee is coming to agreements on the protocol for an international multi-centre study to demonstrate how Respiri’s platform can impact patients. This will be helpful in reducing hospitalisations, improving patient outcomes and lower medical costs.
Respiri believes wheezo is the revolutionary device needed to help patients self-monitor and better manage their asthma.
Despite the news, the company is down 1.05 per cent with shares trading at 9.4 cents each at 2:34 pm AEDT.
